Taft Foley III, an 18-year-old high school senior, co-founded Texas Mobile Medical Labs. Photo courtesy of Texas Mobile

An 18-year old high school senior from the Houston area mobilized his medical knowledge as one of the youngest EMTs in Texas and co-founded a mobile lab which can provide COVID-19 results in 15 minutes.

Texas Mobile Medical Labs was created to counteract testing delays that bogged down how quickly patients received results. The mobile lab currently operates in a van and a tent outside a community center in the Post Oak area for patients who prefer to come to them. For those that can't, the mobile lab can travel to any patient or business location for employee testing in the Houston area after they set up an appointment.

"This summer I become an EMT, training at the Texas EMS Academy in Corpus Christi," says Taft Foley III, co-founder of Texas Mobile Medical Labs. "When I got back to Houston I was asked to take a COVID-19 test, but I was met with a line that wrapped around the entire building and took two hours just to get inside."

According to Foley, that spurred him into finding a better way to get results to people quickly.

"I did my research and found a better alternative to increase testing and reduce waiting times," says Taft. "The antigen test works in 15 minutes, which makes them amenable to point-of-care use. That's when I really got the idea of going out to our patients for the test so that they don't have to leave home."

The tests are performed with a nasal swab, which then detects a viral protein in an actively infected person, giving accurate and fast results.

Antigens are molecules capable of stimulating an immune response. The SARS-CoV-2 that causes COVID-19 has several known antigens including its nucleocapsid phosphoprotein and spike glycoprotein, which are the visible protrusions on its surface.

Antigen tests reveal if a person is currently infected with a pathogen such as the SARS-CoV-2 virus. Once the infection is gone, the antigen disappears.

Although antigen tests typically have lower sensitivity than a traditional PCR test, that detects the virus through its genetic material, they provide tests rapidly and are relatively cheaper to produce.

"Getting this test to as many people as possible as fast as possible is essential," says Taft. "People need to know whether or not they need to stay home and if they're at risk of spreading the virus to others."

The results are sent to patients via text message or email, giving individuals peace of mind quickly if they are not infected and allowing those with COVID-19 to quarantine themselves and those they have exposed.

The test cost ranges from $100 to $150 for individuals, according to their website, depending on if testers would like to go to their tent location or take advantage of their mobile lab. While they currently do not accept insurance, most insurance companies will reimburse some or all of the cost of the test.

You can reach the Texas Mobile Medical lab at (936) 333-3333 if you have COVID-19 symptoms and would like to schedule an appointment for testing.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

West Coast innovation organization unveils new location in Houston suburb to boost Texas tech ecosystem

plugging in

Leading innovation platform Plug and Play announced the opening of its new flagship Houston-area location in Sugar Land, which is its fourth location in Texas.

Plug and Play has accelerated over 2,700 startups globally last year with corporate partners that include Dell Technologies, Daikin, Microsoft, LG Chem, Shell, and Mercedes. The company’s portfolio includes PayPal, Dropbox, LendingClub, and Course Hero, with 8 percent of the portfolio valued at over $100 million.

The deal, which facilitated by the Sugar Land Office of Economic Development and Tourism, will bring a new office for the organization to Sugar Land Town Square with leasing and hiring between December and January. The official launch is slated for the first quarter of 2025, and will feature 15 startups announced on Selection Day.

"By expanding to Sugar Land, we’re creating a space where startups can access resources, build partnerships, and scale rapidly,” VP Growth Strategy at Plug and Play Sherif Saadawi says in a news release. “This location will help fuel Texas' innovation ecosystem, providing entrepreneurs with the tools and networks they need to drive real-world impact and contribute to the state’s technological and economic growth."

Plug and Play plans to hire four full-time equivalent employees and accelerate two startup batches per year. The focus will be on “smart cities,” which include energy, health, transportation, and mobility sectors. One Sugar Land City representative will serve as a board member.

“We are excited to welcome Plug and Play to Sugar Land,” Mayor of Sugar Land Joe Zimmerma adds. “This investment will help us connect with corporate contacts and experts in startups and businesses that would take us many years to reach on our own. It allows us to create a presence, attract investments and jobs to the city, and hopefully become a base of operations for some of these high-growth companies.”

The organization originally entered the Houston market in 2019 and now has locations in Bryan/College Station, Frisco, and Cedar Park in Texas.